Olema announced on 26 May 2026 a clinical trial collaboration and supply agreement with Bayer to test OP-3136, Olema’s oral KAT6 inhibitor, with Nubeqa (darolutamide) in about 36 patients with metastatic castration-resistant prostate cancer, with study initiation expected in H2 2026. Olema announcement, SEC exhibit

Bayer supplies darolutamide, Olema leads the study, combined-use clinical data and inventions are jointly owned, and Olema retains full global commercial and marketing rights to OP-3136. Olema announcement

60-second thesis frame

This is a signal that Olema wants OP-3136 to be more than a breast-cancer follow-on asset, but the investability question is whether KAT6 inhibition can show clean combinability and early activity in androgen receptor-driven prostate cancer without adding hematologic toxicity that blocks dose intensity. The near-term confidence builder is not the Bayer supply agreement itself, it is whether ASCO 2026 Phase 1 data show a tolerability, pharmacodynamic, and mCRPC activity profile strong enough to justify moving from exploratory biology into a crowded prostate-cancer sequence. Olema has already disclosed preliminary OP-3136 monotherapy findings including no dose-limiting toxicities up to 45 mg daily, tumor shrinkage in 13 of 19 response-evaluable patients, and 2 confirmed partial responses across tumor types, but the dataset is early, heterogeneous, and company-reported. Olema ASCO data release Darolutamide is an established androgen receptor inhibitor, but its major recent regulatory momentum is in metastatic hormone-sensitive disease, not as a new mCRPC combination backbone. FDA darolutamide approval page, EMA Nubeqa page

The seven diligence questions

Clinical

• Does OP-3136 show enough mCRPC-specific signal, not just pooled solid-tumor activity, to support the biological leap into prostate cancer?
• Can OP-3136 plus darolutamide preserve dose intensity without additive anemia, neutropenia, fatigue, dysgeusia, or discontinuations that would weaken real-world use? Olema’s early monotherapy dataset reported dysgeusia, anemia, and neutropenia as common treatment-related adverse events. Olema ASCO data release

Payer or Access

• If activity emerges in mCRPC, what line of therapy and biomarker-defined population would make the combination reimbursable against entrenched ARPI, PARP, radioligand, chemotherapy, and clinical-trial options?
• Would payers view KAT6 plus AR inhibition as a differentiated mechanism or as another costly oral-oncology add-on requiring response durability, clear sequencing logic, and evidence after prior ARPI exposure?

Ops or Adoption

• Can Olema run a prostate-cancer combination study efficiently while its lead capital and management focus remain tied to palazestrant Phase 3 execution?

Competitive

• What is the defensible wedge versus other epigenetic, AR-pathway, PARP, AKT, radioligand, and immuno-oncology approaches in mCRPC, especially if the first readout is only safety and preliminary activity?

Team or Cap table

• Does the Bayer collaboration validate external interest in OP-3136, or is it mainly a low-commitment drug-supply arrangement with limited strategic read-through?

Red flags

• The dedicated OP-3136 plus darolutamide trial does not appear to be separately visible yet in the public ClinicalTrials.gov record I found, while Olema states initiation is expected in H2 2026. I would privilege the company release for planned timing, but treat trial design details as incomplete until a registry record posts. ClinicalTrials.gov OP-3136 study, Olema announcement
• Any grade 3 or higher hematologic toxicity, recurrent dose interruptions, or tolerability issues in combination would pressure the central “combinable epigenetic agent” thesis.
• Early activity that is confined to breast cancer, or absent in the mCRPC subgroup, would weaken the “breast cancer and beyond” narrative.

Next catalyst

30 May 2026, Olema’s ASCO poster for the Phase 1 first-in-human OP-3136 study, followed by the posting or initiation of the OP-3136 plus darolutamide Phase 1b/2 study in H2 2026. Olema ASCO presentation details, Olema collaboration announcement

FAQ

What exactly changed in Olema Oncology’s “clinical trial collaboration and supply agreement with Bayer” announcement on 26 May 2026, and why does it matter for mCRPC?

Olema said Bayer will supply darolutamide for a planned Phase 1b/2 study of OP-3136 plus darolutamide in about 36 patients with metastatic castration-resistant prostate cancer. The strategic point is that OP-3136 is moving into a prostate-cancer combination setting, giving investors a way to test whether KAT6 inhibition has relevance beyond Olema’s breast-cancer core. Olema announcement

What is the regulatory context for darolutamide after Olema’s 26 May 2026 Bayer collaboration news?

Darolutamide is already approved in the US for metastatic castration-sensitive prostate cancer, with FDA citing ARANOTE rPFS benefit and no statistically significant OS improvement at final analysis. It is also authorised in the EU for nmCRPC and mHSPC settings, but Olema’s announced study is in mCRPC, so the combination remains investigational. FDA darolutamide approval page, EMA Nubeqa page

Which OP-3136 data matter most after Olema’s 26 May 2026 Bayer collaboration news?

The most relevant data are the Phase 1 safety, pharmacokinetic, pharmacodynamic, and tumor-activity signals due at ASCO 2026, especially any mCRPC-specific observations. Olema’s preliminary company-reported data showed no dose-limiting toxicities up to 45 mg daily, 13 of 19 response-evaluable patients with tumor shrinkage, and 2 confirmed partial responses, but this is early and cross-tumor. Olema ASCO data release

What safety issues matter after Olema’s 26 May 2026 OP-3136 plus darolutamide announcement?

The watch items are hematologic toxicity, fatigue, dysgeusia, treatment interruptions, and whether OP-3136 can combine with an AR inhibitor without eroding adherence. Olema’s early monotherapy update listed dysgeusia, anemia, and neutropenia among common treatment-related adverse events. Olema ASCO data release

How could payer or HTA views shape OP-3136 plus darolutamide after the 26 May 2026 announcement?

For access, the combination would likely need a clear line-of-therapy position, durable benefit, and differentiation from existing prostate-cancer options. NICE’s 2025 darolutamide guidance in hormone-sensitive metastatic prostate cancer includes a commercial access arrangement, which is a reminder that even established AR inhibitors face value-based scrutiny in the UK. NICE TA1109

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 27 May 2026, 04:26 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Olema Oncology; Olema Pharmaceuticals; Bayer; Nubeqa; darolutamide; OP-3136; KAT6; KAT6A/B; mCRPC; metastatic castration-resistant prostate cancer; metastatic hormone-sensitive prostate cancer; mHSPC; nmCRPC; androgen receptor inhibitor; epigenetic therapy; prostate cancer; breast cancer; ER+/HER2-; palazestrant; OP-1250; ASCO 2026; Phase 1b/2; Phase 1; ClinicalTrials.gov; NCT06784193; FDA; EMA; NICE; TA1109; ARANOTE; androgen deprivation therapy; hematologic toxicity; dysgeusia; anemia; neutropenia; payer access; oncology combinations; solid tumors